---
title: "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation"
description: "RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic s"
url: "https://www.clareohealth.com/clinical-trials/NCT00079222"
---

RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation. PURPOSE: This randomized clinical trial is studying voriconazole to see how well it works compared to itraconazole in preventing fungal infections in patients who are undergoing allogeneic hematopoietic stem cell transplantation.

## Key Facts

**ID:** NCT00079222
**Status:** COMPLETED
**Phase:** NA
**Type:** INTERVENTIONAL
**Sponsor:** Jonsson Comprehensive Cancer Center

## About This Study

This clinical trial is testing voriconazole, an antifungal medication, against itraconazole, another antifungal, to see which one is better at preventing fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation (a type of stem cell transplant). It is for patients aged 12 and older who are preparing for this transplant.

## Detailed Description

OBJECTIVES: * Compare the safety and tolerability of voriconazole vs itraconazole for the prevention of fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation. OUTLINE: This is a randomized study. Patients are stratified according to donor type (related vs unrelated). Patients are randomized to 1 of 2 treatment arms. * Arm I: Beginning after allogeneic hematopoietic stem cell transplantation (AHSCT), patients receive voriconazole IV twice daily on days 1-14 and then orally\* twice daily on days 15-100. * Arm II: Beginning after AHSCT, patients receive itraconazole IV twice daily on days 1-2, once daily on days 3-14, and then orally\* twice daily on days 15-100. NOTE: \*Patients unable to tolerate oral medication may continue IV medication beyond day 14. In both arms, treatment continues in the absence of unacceptable toxicity or an invasive fungal infection. Patients requiring corticosteroid therapy for graft-versus-host disease continue to receive voriconazole or itraconazole beyond day 100. Patients are followed until day 180 post-transplantation. PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.

## Conditions

- Cancer

## Interventions

**DRUG: itraconazole**


**DRUG: voriconazole**


## Eligibility

DISEASE CHARACTERISTICS: * Undergoing allogeneic hematopoietic stem cell transplantation * No invasive yeast infection within the past 8 weeks * Colonized or superficial infect…

## Who Can Participate

**Minimum age:** 12

**Maximum age:** 120

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

## Contact Information

## Important Dates

**Study start:** November 1, 2003

**Last updated:** August 3, 2020

## Consider Discussing with Your Care Team

### Worth Discussing If

- You are undergoing allogeneic hematopoietic stem cell transplantation.
- You want to explore options for preventing fungal infections during your treatment.
- You have not had any serious yeast or mold infections in the past 8 weeks.

### Questions to Ask

- What are the main differences between voriconazole and itraconazole?
- How will the side effects of these medications be managed?
- What should I do if I cannot tolerate oral medication?
- How often will I need to come in for treatment and follow-up?
- What are the signs of a fungal infection I should watch for?
- How will this treatment fit with my overall care plan?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00079222)
